Medroxyprogesterone acetate impairs memory and alters the GABAergic system in aged surgically menopausal rats.

B Blair Braden, Joshua S Talboom, Ian D Crain, Alain R Simard, Ronald J Lukas, Laszlo Prokai, Melissa R Scheldrup, Bronson L Bowman, Heather A Bimonte-Nelson
Author Information
  1. B Blair Braden: Department of Psychology, Arizona State University, Tempe, AZ 85287, USA.

Abstract

In women, medroxyprogesterone acetate (MPA) is the most commonly used progestin component of hormone therapy (HT). In vitro, MPA negatively impacts markers of neuronal health and exacerbates experimentally-induced neurotoxicity. There is in vitro evidence that these factors are driven by GABAergic and neurotrophic systems. Whether these effects translate to a negative impact on brain function has not been tested in vivo, clinically or preclinically. Here we evaluate the mnemonic and neurobiological effects of MPA in the surgically menopausal rat. Aged ovariectomized (OVX) rats were given subcutaneous vehicle, natural progesterone, low-dose MPA or high-dose MPA. Multiple cognitive domains were analyzed via the water radial-arm maze (WRAM) and Morris maze (MM). Cognitive brain regions were assayed for changes in the GABAergic system by evaluating GAD protein, the synthesizing enzyme for GABA, and neurotrophins. On the WRAM, both progestin types impaired learning. Further, high-dose MPA impaired delayed memory retention on the WRAM, and exacerbated overnight forgetting on the MM. While neurotrophins were not affected by progesterone or MPA treatment, both progestin types altered GAD levels. MPA significantly and progesterone marginally decreased GAD levels in the hippocampus, and both MPA and progesterone significantly increased GAD levels in the entorhinal cortex. These findings suggest that MPA, the most commonly used progestin in HT, is detrimental to learning and two types of memory, and modulates the GABAergic system in cognitive brain regions, in aged surgically menopausal rats. These findings, combined with in vitro evidence that MPA is detrimental to neuronal health, indicates that MPA has negative effects for brain health and function.

References

  1. J Clin Neurophysiol. 1992 Apr;9(2):252-63 [PMID: 1350592]
  2. Neuroreport. 2004 Dec 3;15(17):2659-63 [PMID: 15570173]
  3. Neurobiol Learn Mem. 1995 Jul;64(1):83-96 [PMID: 7582815]
  4. Eur J Neurosci. 2009 Feb;29(3):447-54 [PMID: 19175406]
  5. Endocrinology. 2002 Jan;143(1):205-12 [PMID: 11751611]
  6. Brain Res Rev. 2007 Aug;55(1):78-88 [PMID: 17561265]
  7. Neurobiol Aging. 2003 Jan-Feb;24(1):37-48 [PMID: 12493549]
  8. Brain Res. 2000 Apr 28;863(1-2):151-9 [PMID: 10773203]
  9. J Neurosci Res. 2007 Aug 15;85(11):2441-9 [PMID: 17549730]
  10. JAMA. 2004 Jan 7;291(1):47-53 [PMID: 14709575]
  11. Neurosci Lett. 2002 Aug 2;328(1):50-4 [PMID: 12123857]
  12. Horm Behav. 2005 Mar;47(3):371-5 [PMID: 15708768]
  13. Psychoneuroendocrinology. 1988;13(4):345-57 [PMID: 3067252]
  14. Endocrinology. 1992 Dec;131(6):2697-702 [PMID: 1446611]
  15. Horm Behav. 2002 Nov;42(3):284-93 [PMID: 12460588]
  16. Physiol Behav. 2000 Feb;68(4):495-9 [PMID: 10713289]
  17. Neurobiol Aging. 2011 Apr;32(4):680-97 [PMID: 19883953]
  18. Pharmacol Biochem Behav. 1993 May;45(1):77-83 [PMID: 8516376]
  19. J Steroid Biochem. 1987 Mar;26(3):313-9 [PMID: 2953940]
  20. Physiol Behav. 2009 Apr 20;97(1):58-61 [PMID: 19394921]
  21. Br Med J. 1977 Jan 8;1(6053):104-5 [PMID: 188512]
  22. Psychopharmacology (Berl). 2000 Apr;149(2):129-39 [PMID: 10805607]
  23. Gynecol Obstet Invest. 1999;47(1):29-36 [PMID: 9852389]
  24. J Neurosci. 2003 Nov 5;23(31):10013-20 [PMID: 14602815]
  25. Gynecol Endocrinol. 2006 Jul;22(7):355-61 [PMID: 16864144]
  26. J Neurochem. 1980 Mar;34(3):609-13 [PMID: 7354335]
  27. Nature. 1982 Jun 24;297(5868):681-3 [PMID: 7088155]
  28. Hear Res. 2000 Sep;147(1-2):251-60 [PMID: 10962189]
  29. Neuron. 2008 Jan 24;57(2):290-302 [PMID: 18215625]
  30. JAMA. 2004 Jun 23;291(24):2947-58 [PMID: 15213206]
  31. Birth Defects Res B Dev Reprod Toxicol. 2007 Apr;80(2):84-97 [PMID: 17342777]
  32. Horm Behav. 2009 Mar;55(3):454-64 [PMID: 19101559]
  33. J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):205-13 [PMID: 17052903]
  34. Psychoneuroendocrinology. 1999 Feb;24(2):161-73 [PMID: 10101725]
  35. Psychoneuroendocrinology. 1999 Oct;24(7):727-41 [PMID: 10451908]
  36. J Pharmacol Exp Ther. 1999 Feb;288(2):866-78 [PMID: 9918601]
  37. Am J Obstet Gynecol. 1973 May 1;116(1):115-8 [PMID: 4348893]
  38. JAMA. 2003 May 28;289(20):2651-62 [PMID: 12771112]
  39. N Engl J Med. 1975 Dec 4;293(23):1164-7 [PMID: 1186789]
  40. J Biol Chem. 1985 Dec 5;260(28):15266-72 [PMID: 2933398]
  41. Psychoneuroendocrinology. 2001 May;26(4):339-62 [PMID: 11259856]
  42. FASEB J. 1992 Mar;6(6):2311-22 [PMID: 1347506]
  43. Pharmacol Biochem Behav. 1992 Apr;41(4):767-71 [PMID: 1350684]
  44. Br J Clin Pharmacol. 1992 Mar;33(3):293-8 [PMID: 1576050]
  45. Brain Res. 2002 May 3;934(2):125-31 [PMID: 11955475]
  46. Dementia. 1995 Mar-Apr;6(2):99-107 [PMID: 7606287]
  47. Neuroscience. 2005;132(2):399-407 [PMID: 15802192]
  48. Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):2059-65 [PMID: 10479646]
  49. Adv Data. 2004 Dec 10;(350):1-36 [PMID: 15633582]
  50. Neurobiol Aging. 2000 Jan-Feb;21(1):107-16 [PMID: 10794855]
  51. J Neurosci. 2002 Dec 15;22(24):10985-95 [PMID: 12486194]
  52. Biol Reprod. 1979 Aug;21(1):193-203 [PMID: 573635]
  53. Rapid Commun Mass Spectrom. 2001;15(21):2041-5 [PMID: 11675672]
  54. Behav Neurosci. 2004 Aug;118(4):707-14 [PMID: 15301598]
  55. Psychoneuroendocrinology. 1992 Oct;17(5):485-95 [PMID: 1484915]
  56. J Neurosci. 1996 Sep 1;16(17):5437-42 [PMID: 8757256]
  57. Psychopharmacology (Berl). 2008 Aug;199(2):161-8 [PMID: 18551282]
  58. Behav Neurosci. 2003 Dec;117(6):1395-406 [PMID: 14674857]
  59. Behav Neurosci. 1984 Dec;98(6):946-54 [PMID: 6439229]
  60. Behav Brain Res. 2002 Jul 18;133(2):261-70 [PMID: 12110459]
  61. Neurochem Res. 1991 Mar;16(3):215-26 [PMID: 1780024]
  62. Brain Res. 1998 Mar 2;785(2):236-44 [PMID: 9518631]
  63. Eur J Neurosci. 2006 Jul;24(1):229-42 [PMID: 16882019]
  64. Behav Brain Res. 1993 Dec 20;58(1-2):91-8 [PMID: 7907882]
  65. Neuroreport. 2002 May 7;13(6):825-30 [PMID: 11997695]
  66. Hear Res. 2000 Sep;147(1-2):175-82 [PMID: 10962183]
  67. J Womens Health (Larchmt). 2002 Oct;11(8):703-18 [PMID: 12570037]
  68. Physiol Behav. 2000 Aug-Sep;70(3-4):311-7 [PMID: 11006429]
  69. N Engl J Med. 1975 Dec 4;293(23):1167-70 [PMID: 171569]

Grants

  1. R01 AG028084/NIA NIH HHS
  2. R03 AG023925/NIA NIH HHS
  3. AG027956/NIA NIH HHS
  4. AG028084/NIA NIH HHS
  5. P01 AG027956/NIA NIH HHS

MeSH Term

Animals
Contraceptive Agents, Female
Female
Hippocampus
Medroxyprogesterone Acetate
Memory Disorders
Menopause
Ovariectomy
Rats
Rats, Inbred F344
gamma-Aminobutyric Acid

Chemicals

Contraceptive Agents, Female
gamma-Aminobutyric Acid
Medroxyprogesterone Acetate

Word Cloud

Created with Highcharts 10.0.0MPAprogestinGABAergicbrainprogesteroneGADvitrohealtheffectssurgicallymenopausalratsWRAMsystemtypesmemorylevelsacetatecommonlyusedHTneuronalevidencenegativefunctionhigh-dosecognitivemazeMMregionsneurotrophinsimpairedlearningsignificantlyfindingsdetrimentalagedwomenmedroxyprogesteronecomponenthormonetherapynegativelyimpactsmarkersexacerbatesexperimentally-inducedneurotoxicityfactorsdrivenneurotrophicsystemsWhethertranslateimpacttestedvivoclinicallypreclinicallyevaluatemnemonicneurobiologicalratAgedovariectomizedOVXgivensubcutaneousvehiclenaturallow-doseMultipledomainsanalyzedviawaterradial-armMorrisCognitiveassayedchangesevaluatingproteinsynthesizingenzymeGABAdelayedretentionexacerbatedovernightforgettingaffectedtreatmentalteredmarginallydecreasedhippocampusincreasedentorhinalcortexsuggesttwomodulatescombinedindicatesMedroxyprogesteroneimpairsalters

Similar Articles

Cited By